Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander J Thompson

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Internal Medicine Journal|September 5, 2024
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapyNatalie Yu, Tanya Lee, Daniel Tassone, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
BMJ Open|July 3, 2024
Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (the QuickStart Study): a cluster randomised cross-over trial protocolJoseph S Doyle, Katherine Heath, Imogen Elsum, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2021
Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal FistulasMichael De Gregorio, Tanya Lee, Krupa Krishnaprasad, et al.
Springerplus|September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Cancers|December 23, 2023
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie Ngu, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trialsEdward J Gane, Stephen Pianko, Stuart K Roberts, et al.
Cancers|June 19, 2024
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Journal of Hepatology|June 28, 2011
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patientsAlexander J Thompson, Paul J Clark, Abanish Singh, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Internal Medicine Journal|September 5, 2024
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapyNatalie Yu, Tanya Lee, Daniel Tassone, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
BMJ Open|July 3, 2024
Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (the QuickStart Study): a cluster randomised cross-over trial protocolJoseph S Doyle, Katherine Heath, Imogen Elsum, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2021
Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal FistulasMichael De Gregorio, Tanya Lee, Krupa Krishnaprasad, et al.
Springerplus|September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Cancers|December 23, 2023
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie Ngu, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trialsEdward J Gane, Stephen Pianko, Stuart K Roberts, et al.
Cancers|June 19, 2024
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Journal of Hepatology|June 28, 2011
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patientsAlexander J Thompson, Paul J Clark, Abanish Singh, et al.
Pageof 18